Phase 2 N=27 Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Hypoparathyroidism
Primary: Serum Calcium Level — 2; 1.92 mmol/liter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=124 Use of NPSP558 in the Treatment of Hypoparathyroidism
Hypoparathyroidism
Primary: The Percentage of Subjects Who Met the Triple Efficacy Endpoint Criteria at Week 24. — 2.5; 54.8 percentage of participants — p=<0.001
Phase 3 N=114 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
Chronic Allograft Nephropathy · Chronic Kidney Disease · Chronic Renal Failure
Primary: Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) — 3.5; 78.9 percentage…
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
Phase 2 N=10 PTH-independent Effects of Encaleret
Post-Surgical Hypoparathyroidism
Primary: Percent Change in Fractional Excretion of Calcium (FECa) — -39 percentage of change
Phase 4 N=39 A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
Chronic Hypoparathyroidism · Hypoparathyroidism
Primary: Change From Baseline (402) in Concentration of Albumin-corrected Serum Calcium (ACSC) at Month 6 — -0.005 Millimole per liter (mmol/L)
Phase 2 N=1,553 Studies of Elevated Parathyroid Activity
Hyperparathyroidism · Hypercalcemia · Parathyroid Neoplasm
Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants
Phase 3 N=46 Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
Primary Hyperparathyroidism · Parathyroid Adenoma · Parathyroid Hyperplasia
Primary: Change in Lumbar Spine Bone Mineral Density — 0.030; 0.042; -0.016 g/cm^2 — p=< 0.00001
N/A N=240 Opioid Use After Thyroid and Parathyroid Surgeries
Thyroidectomy · Parathyroidectomy · Opioid Use
Primary: New Opioid Discharge Prescriptions — 128; 28 Participants
Phase 2 N=20 Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
Hypoparathyroidism · Hypocalcemia · Autoimmune Polyendocrine Syndrome Type 1
Primary: Mean Serum Calcium in Children and Young Adults — 2.02; 1.88 mmol/liter — p=0.02
N/A N=76 A Comparative Analysis of Hypocalcemia Incidence in Patients Undergoing Thyroidectomy: Ligasure vs Conventional Ligation of Vessels by Knot Tying
Hypocalcemia After Total Thyroidectomy · Hypocalcemia
Primary: Number of Participants With Hypocalcemia — 4; 3 participants
Phase 4 N=93 A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)
Hypoparathyroidism
Primary: Change From Baseline in Hypoparathyroidism Symptom Diary (HypoPT-SD) Symptom Subscale Score at Week 26 — -0.93; -1.46 score on a scale — p==0.003
N/A N=4 Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas
Parathyroid Disease
Primary: Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality — 80 percentage of adenomas detected
Phase 3 N=70 Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery
Cardiac Surgery Intensive Care Treatment · Delayed Recovery From Anaesthesia · Euthyroid Sick Syndrome
Primary: Change in Glasgow Coma Scale (GCS) From Intervention Initiation to ICU Discharge (Δ) — 6.65; 2.69 Score on a scale
Phase 4 N=36 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Graves Disease · Hyperthyroidism
Primary: Blood Loss During Surgery — 61.67; 161.67 mL
Phase 3 N=42 Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
Hypoparathyroidism
Primary: Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 8, Based on Investigator Prescribed Data. — 21.1; 26.1 percentage of participants — p=>0.999
Phase 3 N=51 A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)
Hypoparathyroidism
Primary: Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) — 13; 48 Participants
Phase 3 N=62 HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism
Hypoparathyroidism
Primary: Change in Dose of Calcium Supplementation — 37 percent change in dose
N/A N=79 Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients
Hyperparathyroidism · Disorders of Parathyroid Gland
Primary: Rate of Achieving the Target on Blood Intact Parathyroid Hormone Level According to Kidney Development Improvement Global Outcome (KDIGO) Guidelines. — 30.8; 57.1; 90.0…
Phase 3 N=24 A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary
Hypoparathyroidism
Primary: Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 24, Based on Investigator Prescribed Data. — 75.0 percentage of participants
N/A N=79 Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
Parathyroid Diseases · Parathyroid Dysfunction · Parathyroid Neoplasms
Primary: Median Number of Frozen Sections (or Parathyroid Aspirate) Sent for Analysis — 0; 0 frozen aspirate samples
Phase 3 N=98 18F-Fluorocholine for the Detection of Parathyroid Adenomas
Hyperparathyroidism, Primary
Primary: Proportion of True Positives for the Overall Detection of the Abnormal Parathyroid Adenoma — 0.75 proportion of participants
Phase 4 N=99 Perioperative Administration of Pregabalin for Pain After Robot-assisted Endoscopic Thyroidectomy
Pain, Postoperative
Primary: Pain Scores (VNRS) at 1, 6, 24, 48 Hours Postoperatively. — 6; 6; 3; 2 VNRS
Phase 2 N=59 A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism
Hypoparathyroidism · Endocrine System Diseases · Parathyroid Diseases
Primary: Efficacy - Primary Endpoint During the Blinded Period — 50.0; 40.0; 60.0; 26.7 Percentage of participants — p== 0.2635
Early Phase 1 N=11 7 Day Continuous Parathyroid Hormone IV Infusion
Osteoporosis · Bone Diseases, Endocrine · Hyperparathyroidism
Primary: Participants With Dose Limiting Toxicity — 0; 2 participants
N/A N=43 Peri-Operative Steroid Management in Patients
Pituitary Adenoma · Pituitary Diseases
Primary: Number of Participants With Adrenal Insufficiency — 2; 1 Participants
Phase 2 N=132 AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism
Chronic Hypoparathyroidism
Primary: Treatment Emergent Adverse Events (TEAEs) — 2; 3; 5; 1 Participants
Phase 3 N=46 Effect of Vitamin D Treatment in Primary Hyperparathyroidism
Vitamin D Deficiency · Primary Hyperparathyroidism · Hypercalcemia
Primary: Decrease in Preoperative P-PTH — -2.2; 0.2 pmol/l
Phase 3 N=61 Early Levothyroxine Post Radioactive Iodine
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
N/A N=146 Swallowing Function Before and After Surgery for Thyroid Goiter
Hypothyroidism
Primary: Swallowing Quality of Life — 84.6; 92.3; 81.2; 87.1 units on a scale — p=0.0007